NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc.
NEW YORK, Nov. 4, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc.
Largest peer-reviewed study of nonendoscopic esophageal precancer testing to date demonstrates the efficiency and scalability of EsoCheck® cell collection in under two minutes NEW YORK, Nov. 3, 2026 /PRNewswire/ --
Conference Call and Webcast at 8:30 AM ETNEW YORK, Oct. 30, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company,
Conference Call and Webcast at 8:30 AM ETNEW YORK, Oct. 29, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics
DENVER, Oct. 23, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — With U.S. crude hovering above $100 a barrel, investors are looking beyond the energy trade for smaller companies with potentially transformative
Lucid is now submitting Medicare claims and receiving payments at EsoGuard's established Clinical Laboratory Fee Schedule rateSeries C Preferred Stock private placement with existing long-term shareholders
Medicare Advisory Panel recommends maintaining EsoGuard's original gapfill payment basis under the Clinical Laboratory Fee ScheduleAMA CPT Editorial Panel approves a new Category III CPT code for non-endoscopic cell
Veris Health accelerated its commercial engagement with OSU-The JamesVeris Health implantable physiological monitor achieved development milestones towards upcoming FDA submissionLucid Diagnostics secured first
Recognized 2Q26 revenue of $1.5 millionProcessed 2,770 EsoGuard ® testsSecured first laboratory benefit manager (LBM) EsoGuard coverage policyConference call and webcast to be held today, August 13, at 8:30 AM EDTNEW
Concert's policy recognizes EsoGuard ® as the only esophageal precancer test meeting its coverage criteriaNEW YORK, Aug. 5, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the
NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc.
Conference Call and Webcast at 8:30 AM ETNEW YORK, July 31, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company,
Conference Call and Webcast at 8:30 AM ETNEW YORK, July 30, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics
Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submissionLucid Diagnostics continued building commercial momentum and strengthened its balance sheet
